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Abstract: There is currently less experience with inhaled tobramycin in non-cystic fibrosis bronchiectasis than in cystic 
fibrosis (CF). Intravenous formulation and solution for inhalation (TSI) have been studied in non-CF bronchiectasis 
patients with chronic P. aeruginosa bronchial infection. An improvement in clinical parameters and a reduction in 
bacterial density have been shown with both inhaled solutions in these patients. However, further trials are needed to 
determine the most effective dose and administration protocol in these patients. Based on the current evidence, 
recommendations cannot be made regarding the use of TSI to treat exacerbations. Although no systemic toxicity has been 
reported in studies specifically investigating this treatment, patients with known kidney disease or ear disorders should be 
treated with caution. Adverse respiratory effects are reported to be more common in non-CF patients than in CF patients, 
who tend to be non-smokers and younger. Research is being conducted into the possibility of combining tobramycin with 
other antibiotics to increase its antibacterial activity. In this review we will present and discuss the published evidence 
regarding the use of inhaled tobramycin in non–CF bronchiectasis. 
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INTRODUCTION 
 The aim of antibiotic treatment in acute bronchial 
infection is to kill and eradicate bacteria. However, in 
chronic bronchial infection, where bacterial eradication is 
usually not feasible, the aim of treatment is to reduce the 
bacterial load and thus reduce the inflammatory response. 
 Managing patients with bronchiectasis and chronic 
bronchial infection is a challenge due to the fact that oral 
antibiotics do not achieve sufficient concentrations at the 
infection site. Administering inhaled antibiotics to these 
patients was first suggested in the 1940s [1]. The intention 
was to release the antibiotic directly into the infected area to 
achieve high concentrations at this site while reducing 
systemic side effects. Various intravenous antibiotics, 
including tobramycin [2-4], have been administered 
empirically for over 40 years at varying doses and using 
different nebulisers especially in patients with cystic fibrosis 
(CF) with chronic Pseudomonas aeruginosa bronchial 
infection, which is associated with high morbidity and 
mortality rates. After the study by Ramsey et al., in which 
patients with CF-related bronchiectasis and chronic P. 
aeruginosa bronchial infection were treated with a specially 
designed aerosol formulation of tobramycin using a new jet 
nebuliser at higher doses than had previously been used [5],  
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few doubts remain as to the efficacy of this treatment in 
these patients [6]. 
 Tobramycin is an aminoglycoside with good in vitro 
antibacterial activity against P. aeruginosa, even surpassing 
gentamicin, and which is also active against other gram-
negative (Enterobacteria, Haemophilus influenzae) and some 
gram-positive aerobic bacteria (Staphilococcus aureus). Its 
antibacterial effect interferes with the synthesis of bacterial 
proteins by altering their cell membrane permeability, 
thereby causing cell death [7]. It is bactericidal at 
concentrations equal to or slightly higher than inhibitory 
concentrations and its effect is concentration-dependent 
under aerobic conditions [8]. In addition to tobramycin’s 
antibacterial effect, it may also inhibit the expression and 
production of Pseudomonas virulence factors and the 
cytotoxic effect of neutrophil-derived myeloperoxidase [7]. 
Like other aminoglycosides, it barely penetrates bronchial 
secretions when administered parenterally and high doses are 
required to achieve sufficient concentrations at the infection 
site, which entails a risk of nephrotoxicity and ototoxicity 
[7]. Administering aminoglycosides via the inhaled route, 
higher concentrations can be obtained at the infection site, so 
reducing systemic absorption and side effects. 
 A review has been published regarding the evidence of 
inhaled tobramycin in patients with CF [9]. However, to the 
best of our knowledge, no review has been made of evidence 
from patients with non-CF bronchiectasis. The aim of this 
review is therefore to analyse the available evidence of 
treatment with tobramycin in patients with non-CF 
bronchiectasis. 
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AVAILABLE FORMULATIONS AND NEBULISERS 
 Intravenous tobramycin sulphate solutions containing 
varying amounts of preservatives and bisulphites, which 
have been related to bronchoconstriction [10], were used for 
many years until tobramycin solution for inhalation (TSI) 
came onto the market. TSI is additive-free and specifically 
designed to be nebulised into the lungs [8]. 
 TSI was approved by the FDA in 1998 for the treatment 
of chronic P. aeruginosa bronchial infection in patients with 
CF [8]. It contains high doses of tobramycin (300 mg), is 
non-pyrogenic and preservative-free, has adjusted pH and 
osmolality, and is supplied in single-dose vials so avoiding 
preparation errors. CF trials have demonstrated the efficacy 
of TSI with the PARI LC PLUS® nebuliser and the 
DeVilbiss Pulmo-Aide® compressor [5]. However, it has also 
been found that when other compressors, such as SystAm 
23ST, MedicAid CR50 and CR60, PARI MASTER® and 
PARI BOY®, have been used with the PARI LC PLUS® 
nebuliser, similar doses of tobramycin are delivered [11]. 
The PARI eFlow®rapid is an electronic nebuliser that 
reduces the nebulisation time of TSI to 7 minutes compared 
with 20 minutes using the PARI LC PLUS® [12]. Initially, 
only the 5 ml formulation, containing 300 mg of tobramycin, 
11.25 mg of sodium chloride, water for injection and 
sulphuric acid, along with sodium hydroxide to adjust the 
pH, was available (TOBI® Novartis AG, Basel, Switzerland) 
although there is now a more concentrated formulation at the 
same dose in 4 ml of preservative-free saline (Bramitob®, 
Chiesi Farmaceutici S.p.A., Parma, Italy) that reduces the 
inhalation time [13] and has demonstrated non-inferiority 
with regards to the 5 ml formulation in CF patients [14]. This 
latter formulation is efficiently nebulised using the PARI LC 
PLUS® nebuliser and the PARI TurboBOY® compressor 
[14]. 
 The dry powder formulation using the T-326 Inhaler is 
the most recent tobramycin formulation to be released on the 
market. The safety and efficacy profile of the 112 mg dose of 
tobramycin inhalation powder (TIP) in 4 capsules every 12 
hours in CF patients is comparable to that of TSI with the 
PARI LC PLUS® nebuliser, but the administration time is 
significantly shorter (an average of 5.6 minutes for TIP vs 
19.7 minutes for TSI) [15]. This formulation also reduces the 
potential for device contamination. No trials have so far been 
published in patients with non-CF bronchiectasis. 
 A new formulation, T100 (VANTOBRA, 170 mg/1.7; 
PARI Pharma GmbH, Stanberg, Germany), is being studied 
in a solution with lower TSI doses and a higher 
concentration. T100 is administered with a drug-specific 
efficient eFlow nebuliser handset with the aim of reducing 
inhalation times [16]. 
TREATMENT OF CHRONIC BRONCHIAL INFECTION 
 It is important to take into account that bacteria behaves 
differently in chronic and acute bronchial infection as this 
has treatment implications. In chronic bronchial infection, 
bacteria grow on the surface of the epithelium without 
invading it in a less virulent manner but they can develop 
persistence mechanisms and cause an inflammatory 
response. The main persistence mechanisms are the 
formation of biofilms and hypermutation [17-19]. Within the 
biofilm, bacteria are in an anaerobic environment which 
reduces their growth activity and, as a result, the antibacterial 
effect of the antibiotic. Since antibiotic treatment tends to 
eliminate the bacteria with more active growth on the 
biofilm surface, antibiotics have to be administered at high 
doses and for prolonged periods in order to interfere with the 
biofilm. 
 It has long been known that chronic bronchial infection 
in CF bronchiectasis should be treated with inhaled 
antibiotics and very specifically in the case of infections 
caused by P. aeruginosa, which is associated to rapid 
progression of pulmonary infection in severe cases of CF 
[19]. The first antibiotic approved for such use in CF was 
TSI. Treatment with 300 mg of TSI twice daily in 28-day on-
off cycles for a total of 24 weeks was studied in a 
multicentre, randomised, placebo-controlled trial involving 
over 500 patients with CF-related bronchiectasis with 
chronic P. aeruginosa bronchial infection. These patients 
were not receiving antibiotic treatment for the chronic 
infection. The treatment improved pulmonary function, 
decreased the density of P. aeruginosa in sputum and 
reduced the risk of exacerbation compared with the placebo 
[5]. The dry powder tobramycin preparation has been shown 
to have an efficacy that is comparable to that of TSI in these 
patients with the same administration regimen [15]. 
 In non-CF bronchiectasis, few studies have been 
performed with inhaled antibiotics probably as a result of the 
heterogeneity of the population, the fact that patients have 
not typically been controlled in specialised units, the 
generally slower progression of lung damage, and the lack of 
interest of the pharmaceutical industry, which has had the 
result that it has repeatedly been not recommended for 
routine use in these patients [20-23]. However, high bacterial 
loads in non-CF bronchiectasis are also associated with local 
and systemic inflammation and a greater risk of 
exacerbations [24], and chronic P. aeruginosa bronchial 
infection has been associated with worse quality of life, a 
greater extent of bronchiectasis, worse lung function [25], 
and greater mortality [26, 27]. As with CF bronchiectasis, 
chronic P. aeruginosa bronchial infection may cause more 
rapid lung function decline if left untreated [28] and can 
potentially be	   modified by the use of nebulized antibiotic 
therapy [29, 30]. In this regard, both the Spanish and British 
bronchiectasis guidelines recommend the use of inhaled 
antibiotics in these patients [31, 32]. 
 Four trials have been published evaluating the efficacy of 
inhaled tobramycin in chronic P. aeruginosa bronchial 
infection patients with stable non-CF bronchiectasis, two of 
which were conducted by the same group in Catalonia using 
a continuously administered intravenous formulation [33, 
34], and two in the USA using TSI [35, 36]. 
 Orriols et al. [33] conducted a trial on 17 patients (mean 
age 62.0±8.5 years in the treatment group and 61.4±10.3 
years in the non-treatment group) who had been treated at 
least once in the preceding three months with oral 
ciprofloxacin at doses of 500 mg every 12 hours for 3 weeks 
due to exacerbation without improvement or recurrence of 
symptoms. All of the patients received intravenous antibiotic 
treatment with ceftazidime and tobramycin for 2 weeks. 
They were subsequently randomly assigned to two groups: 
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one group received the same antibiotics that they had 
received by the intravenous route by inhalation for 12 
months (ceftazidime 1 g every 12 hours in 8 ml of 0.9% 
saline solution and tobramycin 100 mg every 12 hours in 8 
ml of 0.9% saline solution through the System 22 nebuliser 
and CR60 compressor, Medic-Aid, UK) whereas the other 
group received only symptomatic treatment. The number and 
duration of hospitalisations were lower in the patients 
receiving inhaled antibiotics. Only one patient in the 
treatment group required hospitalisation, although this 
patient was admitted four times during the trial period. On 
the other hand, all but one of the patients who received 
symptomatic treatment required hospitalisation. No 
differences were observed regarding the use of oral 
antibiotics. The eradication of P. aeruginosa was not 
achieved in any patient. Despite the advantages of inhaled 
antibiotic therapy over leaving the chronic bronchial 
infection untreated, the administration of two nebulised 
antibiotics with a considerable amount of solution is time-
consuming for patients, making compliance difficult in 
clinical practice. 
 The same group conducted a second trial [34] consisting 
of a placebo-controlled crossover study of 30 patients (mean 
age 64.5 years) with an intravenous tobramycin formulation 
at a higher dose than in the previous trial (300 mg every 12 
hours, TOBRA-GOBENS® 100 mg/2 ml, Normon labs, 
diluted with 0.9% saline solution to obtain an 8 ml solution) 
and placebo (8 ml of 0.9% saline) in two 6-month cycles 
separated by a one-month washout period. The same 
nebuliser and compressor were used as in the previous trial. 
At the start of treatment, the patients were also admitted for 
two weeks of intravenous treatment with two antibiotics 
(ceftazidime and tobramycin). During treatment with inhaled 
tobramycin, in addition to fewer and shorter hospitalisations 
as was found in the previous trial, a decrease in P. 
aeruginosa density in sputum was also observed. The 
bacterial density in sputum returned to baseline values three 
months after ending the treatment. No differences were 
observed with regard to the number of exacerbations, quality 
of life measured by the St. George Respiratory Questionnaire 
(SGRQ) or systemic inflammation markers. 
 Barker et al. [35] conducted a phase II, multicentre, 
placebo-controlled, double-blind randomised trial in the 
United States using 300 mg of TSI twice daily administered 
with the PARI LC PLUS® jet nebuliser and a Pulmo-Aide® 
compressor (DeVilbiss, Somerset, PA). They used the same 
methods and system of administration as the Ramsey et al. 
CF trial [5] published the previous year but applying the 
treatment over a single 28-day period. Seventy-four patients 
(mean age 66.6±13.0 years in the treatment group and 
63.2±13.5 years in the placebo group) in stable state with 
purulent sputum containing at least 104 colony-forming units 
of P. aeruginosa per gram who had not been treated with 
antibiotics in the preceding two weeks were randomly 
assigned to two groups. One group received TSI and the 
other received a placebo (1.25 mg of quinine sulphate in the 
same excipient). The bacterial density of P. aeruginosa in 
sputum significantly decreased in the patients receiving TSI 
by the end of the four weeks of treatment when compared 
with the placebo. This was accompanied by clinical 
improvement although this was only evaluated by the 
investigators’ subjective assessments of the change in the 
patients’ general medical condition as either “improved” or 
“not improved”. As in the trial in CF patients [5], the 
greatest reduction in bacterial density was observed after two 
weeks of treatment and the density was found to have 
increased again two weeks after stopping the treatment, 
although the number of colonies remained lower than for the 
group given the placebo. The extent of bacterial density 
reduction observed in this trial was greater than that 
observed in CF patients [5]. The Barker et al. trial, whilst 
having the largest sample size of the non-CF studies, had 
considerably fewer patients than Ramsey et al. [5]. 
 In the second American trial with TSI, Scheinberg et al. 
[36] enrolled 41 patients (mean age 65.2±13.1 years) with 
purulent sputum who had received four or more courses of 
antibiotics for a respiratory condition in the last 12 months in 
an open-label, multicentre clinical trial. The patients received 
three treatment cycles with TSI (300 mg/5 ml twice-daily) 
for 14 days on followed by 14 days off, using the same 
nebuliser and compressor as in the Barker trial [35]. Upon 
completion of the three treatment cycles, significant 
improvements were observed in the symptom severity score 
as measured by the Patient Symptoms Questionnaire (for 5 
symptoms: severity of cough, shortness of breath, sputum 
production (frequency and severity), fatigue, and wheezing). 
The greatest reduction in severity and intensity was observed 
in sputum production. Sputum colour improved in 43.9% of 
patients, worsened in 4.9% and remained unchanged in 
51.2%. There was also a significant improvement in quality 
of life measured by the SGRQ. A greater reduction was 
found in women than in men with regard to the evaluation of 
symptoms and quality of life. It is worth noting that 78.6% 
of the men had a history of smoking compared with 40.7% 
of the women. 
 Unlike trials in CF, the majority of which have been 
conducted in young populations, none of the three 
randomised trials on adult patients with non-CF 
bronchiectasis showed an improvement in forced expiratory 
volume in 1 second (FEV1) with the inhaled tobramycin 
treatment [33-35]. It is likely that change in lung function in 
these patients is not sufficiently sensitive and should 
therefore not be an endpoint for analysis. Other variables that 
are both more sensitive and more specific in terms of 
reduction in infection should be considered. In fact, almost 
no other treatment, whether using antibiotics [37-41] or 
inhaled corticosteroids [42], has managed to improve FEV1 
in these patients. Only a phase II trial with a selective 
neutrophil elastase inhibitor administered to 38 patients over 
a four-week period has been associated with a significant 
improvement in FEV1 of 100 ml compared with a placebo 
[43]. 
 In the four trials, despite the different methods used and 
the tobramycin formulation administered, beneficial effects 
to bronchiectasis patients with aetiologies other than CF 
were reported. However, none of these studies provided 
detailed data regarded the aetiology of the bronchiectasis of 
the enrolled patients. Whilst smoking habits were not 
specified for either of the Catalonian trials, it is striking that 
in the American trials, 65% of the patients who received TSI 
in the Barker trial [35] and 78.6% of the men in the 
Scheinberg trial [36] had a history of smoking, which could 
involve respiratory diseases caused by smoking in addition 
Evidence of Inhaled Tobramycin in Non-Cystic Fibrosis Bronchiectasis The Open Respiratory Medicine Journal, 2015, Volume 9    33 
to the bronchiectasis. The low prevalence of certain 
aetiologies makes it difficult to conduct trials for each one 
individually and so data should be extrapolated to other 
populations given that ultimately it is the bronchial infection 
that is being treated rather than the cause of bronchiectasis. 
In any case, more trials are needed to determine the most 
effective dose and administration protocol in this population, 
which is generally more elderly and much more 
heterogeneous than the population with CF. Furthermore, we 
need to determine whether the most severe cases should 
receive continued treatment or continue following the current 
recommendations for TSI in CF patients with on-off periods 
or whether to add a second inhaled antibiotic during the off 
period [31]. 
 Although the Murray et al. trial [38] was conducted with 
inhaled gentamicin and not tobramycin, it is worth 
mentioning because this drug is probably equivalent to 
tobramycin in many respects. Sixty-five patients with non-
CF bronchiectasis with chronic bronchial infection caused by 
various pathogenic organisms and at least two exacerbations 
in the preceding year were randomly allocated to receive 
twice-daily nebulized gentamicin (80 mg of gentamicin 
injectable solution reconstituted for nebulization using 0.9% 
saline), or twice-daily nebulized 0.9% saline (5 ml), with a 
Porta-Neb Ventstream® nebuliser (Profile Respiratory 
Systems Ltd, Bognor Regis, West Sussex, UK). Treatment 
with gentamicin was associated with a reduction in sputum 
bacterial density, less sputum purulence, greater exercise 
capacity, improved quality of life (as measured by the SGRQ 
questionnaire and the Leicester Cough Questionnaire) and 
fewer exacerbations compared with placebo. After 
discontinuing the treatment for three months, these 
improvements were not sustained. Data from this trial 
suggest that treatment should be prolonged in order to 
maintain the benefits, that patients with chronic bronchial 
infection caused by bacteria other than P. aeruginosa also 
improve with inhaled antibiotics, that higher doses of 
gentamicin should be studied if they are able to sustain 
longer-term improvements, and that the results of treatment 
will probably be better with more efficient nebulisers. 
 There are no trials comparing inhaled antibiotics in non-
CF bronchiectasis. Two trials have compared TSI with new 
inhaled antibiotics in CF-related bronchiectasis with chronic 
P. aeruginosa bronchial infection [44, 45]. In the first trial, 
TSI, at the dose and using the nebuliser that had already 
proven effective [5] (300 mg in 5 ml administered with the 
PARI LC PLUS® nebuliser), was compared with colistin 
(sulphomethate sodium) (Colomycin® injection, Pharmax 
Ltd, Kent, UK) at a lower dose than what is currently used (1 
mU) and using a less efficient nebuliser (VentstreamTM 
nebuliser, Medic-Aid) for four weeks. The trial concluded 
that although both antibiotics reduced bacterial density and 
had equivalent safety profiles, TSI improved the FEV1 after 
four weeks of treatment while colistin did not. In that trial, 
77.4% of the patients in the group receiving colistin had 
already been receiving it for at least a month prior to the 
trial, while only 3.7% of the patients in the group receiving 
TSI had received it in the preceding month [44]. In the 
second trial, aztreonam for inhalation solution (AZLI) 
(Cayston®, Gilead Sciences Inc.) at a dose of 75 mg three-
times daily was compared with TSI (300 mg twice daily). 
After one treatment cycle with AZLI, the improvement in 
FEV1 was higher than with TSI. In both groups, 
approximately 85% of the patients had received TSI for at 
least three months in the preceding year and none had 
received AZLI [45]. Both trials compared the efficacy of an 
antibiotic to which the trial population had not been 
previously submitted versus another antibiotic that had 
already been widely administered during the previous year. 
In these cases, the results should be evaluated as the non-
inferiority rather than the superiority of the antibiotic used in 
the naive patients versus the antibiotic that had already been 
used. The TSI [5] and AZLI [45] trials in CF demonstrate 
that the greatest effect of the inhaled antibiotic on FEV1 
occurs within the first 15 days of treatment and that the 
effect is subsequently sustained during the trial period. 
Therefore, the effect of the antibiotic on FEV1 improvement 
is not comparable for the two antibiotics. However, these 
trials suggest that the rotation or combination of different 
antibiotics could be a valid therapeutic approach to consider 
in the treatment of chronic bronchial infection in 
bronchiectasis patients. 
 Given the complexity of treating chronic bronchial 
infection with bacteria growing within biofilm and the 
challenges of eradicating bacteria, research is being carried 
out to study the possibility of combining different inhaled 
antibiotics in order to enhance their antibacterial activity. 
Fosfomycin is an antibiotic with bactericidal activity against 
gram-positive and gram-negative bacteria that increases the 
bactericidal activity of tobramycin. A 4:1 
fosfomycin/tobramycin combination showed high 
bactericidal activity in in vitro and in vivo against bacterial 
respiratory pathogens seen in the CF and non-CF 
bronchiectasis populations such as E. coli, H. influenzae, S. 
aureus, Klebsiella spp., and P. aeruginosa [46]. In a 
randomised, placebo-controlled trial in CF patients with 
chronic P. aeruginosa bronchial infection, this combination 
at a dose of 160/40 mg or 80/20 mg twice daily for 28 days 
was able to maintain the improvements in lung function 
attained after 28 days of prior treatment with inhaled 
aztreonam and was well tolerated, although there were fewer 
adverse effects with the 80/20 mg dose [47]. If efficacy is 
confirmed, this combination would make it possible to 
substantially reduce the approved dose of tobramycin in TSI 
in these patients and reduce the potential toxic effects after 
months or years of treatment. The possibility of combining 
tobramycin with other antibiotics, including a macrolide [48] 
or colistin [49], is also being studied. 
TREATMENT OF ACUTE BRONCHIAL INFECTIONS-
EXACERBATIONS 
 The only oral antibiotics available for outpatient use in 
treating exacerbations in patients with chronic P. aeruginosa 
bronchial infection are ciprofloxacin and levofloxacin. 
However, these antibiotics may not always be effective and 
hospitalisation is often required to administer intravenous 
antibiotic treatment, which increases the overall cost and has 
a negative impact on quality of life. Bilton et al. [50] 
conducted a randomised, multicentre, double-blind, placebo-
controlled trial to investigate the effect of adding TSI to oral 
ciprofloxacin for the treatment of exacerbations of non-CF 
bronchiectasis in 53 adult patients with chronic bronchial 
infection caused by ciprofloxacin-sensitive P. aeruginosa 
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(mean age 62±11.4 years). Patients were selected during the 
stable state. At the first exacerbation, they were randomly 
assigned to two treatment groups. One group received 300 
mg (5 ml) of TSI twice daily with the PARI LC PLUS® jet 
nebuliser in addition to 750 mg of oral ciprofloxacin twice 
daily for 14 days. The other group received placebo (1.25 mg 
of quinine sulphate [5 ml]) with the same nebuliser and oral 
ciprofloxacin following the same administration regimen. 
There was a significantly higher reduction in the sputum 
density of P. aeruginosa during treatment in the group 
receiving TSI but no significant differences were observed 
with regard to the reduction seven days after ending the 
treatment. The greater bacterial reduction was not 
accompanied by significant differences in clinical 
improvement in the two groups, which may have been due to 
the increased frequency of wheezing experienced by the 
group receiving TSI. Other efficacy variables such as time-
to-next-exacerbation and time-to-next-exacerbation-
requiring-hospitalization remain to be analysed in future 
studies. 
 Only two trials have been conducted to analyse the effect 
of adding inhaled tobramycin to intravenous antibiotics for 
treatment of exacerbations in CF-related bronchiectasis 
patients with chronic P. aeruginosa bronchial infection. The 
first was conducted 30 years ago [51] in 28 patients with CF 
(age range between 7 and 22 years). It studied an intravenous 
preparation at a dose of 80 mg/8 hours (Bennet twin jet 
nebuliser), which was added to intravenous treatment with 
tobramycin and carbenicillin. The second [52] is more recent 
and was conducted with TSI 300mg twice daily added to 
intravenous tobramycin and colistin. In both trials, the 
treatment with inhaled tobramycin was associated with a 
greater reduction in bacterial density in sputum. In the first 
trial, this decrease was temporary and not accompanied by 
clinical improvement [51] but in the second trial, with higher 
doses of TSI and a more effective nebuliser, the treatment 
was associated with prolonging the time to the next 
exacerbation requiring hospitalisation without an increase in 
adverse effects [52]. 
 Although recommendations cannot currently be made 
regarding the use of inhaled tobramycin for treating 
exacerbations, future trials should analyse its efficacy in 
mild exacerbations in patients refractory to treatment with 
oral ciprofloxacin or in infections caused by resistant P. 
aeruginosa in an attempt to avoid hospitalisations [50]. 
TREATMENT OF INITIAL COLONISATION WITH 
PSEUDOMONAS AERUGINOSA 
 The eradication of P. aeruginosa in chronic bronchial 
infection is very difficult to achieve, particularly in CF-
related bronchiectasis. There is a greater chance of success, 
however, during the period of initial colonisation when P. 
aeruginosa are more sensitive to antibiotics, they are still 
unable to form biofilms, and the bacterial density is low. 
Although several eradication protocols have been studied in 
CF patients with promising results, including inhaled 
tobramycin alone and in combination with oral 
ciprofloxacin, the most effective protocol has yet to be 
determined [53]. 
 We have no knowledge of trials attempting to eradicate 
the initial P. aeruginosa colonisation in non-CF 
bronchiectasis with an inhaled antibiotic. Nevertheless, both 
Spanish and British guidelines recommend early treatment of 
initial P. aeruginosa colonisation with an inhaled antibiotic 
if the attempt to eradicate it with oral ciprofloxacin fails [31, 
32]. 
ADVERSE EFFECTS 
 Inhaled tobramycin is generally well tolerated. Systemic 
absorption in bronchiectasis patients is low. The mean serum 
concentration in patients treated with 300 mg of TSI, 
measured 30 and 60 minutes after administration during 
stable phase, was 0.54 µg/ml and ranged from the lower limit 
of detection (0.18 µg/ml) to 2.64 µg/ml [35]. The serum 
concentration during exacerbations 60 minutes after 
administration was 1.14 µg/ml (SD: 0.68 µg/ml, range: 0.29 
to 2.34 µg/ml) [50]. These data are comparable to the 
concentrations in CF patients [5]. Trials in bronchiectasis 
patients found no renal or vestibular toxicity [33-35, 50], and 
showed only a decrease in creatinine clearance in one trial 
[36] and transitory mild or moderate tinnitus with no 
audiometric changes in another [34]. However, patients with 
impaired kidney function or audiometric disorders are 
excluded from the majority of trials [33, 34, 50] and so 
patients with these conditions should be treated with 
particular caution [8]. Sporadic cases of systemic toxicity 
have been reported both in CF patients [54] and patients with 
conditions other than bronchiectasis in whom there may be 
greater systemic absorption of tobramycin [55, 56]. 
 Compared to the CF trials [5], adverse respiratory effect 
reports are more common in bronchiectasis secondary to 
other aetiologies [33-36, 50]. Bronchospasm was initially 
associated with hypertonic solutions and the presence of 
sulphites or other additives in intravenous preparations [10]. 
In the Orriols et al. trial, the inhaled treatment with an 
unspecified intravenous formulation of tobramycin was 
discontinued in one out of 17 patients due to bronchospasm 
despite intensive bronchodilator treatment being given; the 
patient had a previous history of bronchial hyperreactivity 
[33]. In the Drobnic et al. trial, 10% of the patients had 
bronchospasm, which forced them to discontinue treatment. 
One patient out of 20 experienced shortness of breath and 
wheezing during the first month of treatment and required 
bronchodilator treatment until the end of the trial. The 
intravenous formulation used in this study was TOBRA-
GOBENS® [34]. The rate of adverse respiratory effects with 
TSI was higher than with placebo in the Barker et al. trial (4-
16% of the patients had cough, shortness of breath or 
wheezing associated with TSI) [35]. In the Scheinberg et al. 
trial, 26.8% of patients had cough, 17.1% dyspnoea and 
17.1% wheezing, which were associated with TSI. A total of 
22% of patients were withdrawn from the trial due to side 
effects [36]. Cough and wheezing were identified when 
treating exacerbations, although these symptoms were not 
suspected on measuring changes in FEV1 at 30 minutes 
post-dose on the first day of treatment [50]. The greatest 
differences between patients with CF and those with 
bronchiectasis secondary to other aetiologies, which could 
explain the greater incidence of respiratory side effects 
among the non-CF patients, are the greater age in the non-CF 
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patients (66.6 years vs 20.8 years in CF) and a greater history 
of smoking (65% of patients in the Barker trial [35] and 
53.7% in the Scheinberg trial [36]). It is advisable that the 
first administration of treatment should be given in hospital 
in order to monitor the possibility of any respiratory adverse 
effects [32]. 
 A decrease in the susceptibility of P. aeruginosa to 
antibiotics and the emergence of multi-resistant pathogens 
are major concerns in the use of long-term inhaled antibiotic 
therapy. Clinical trials with inhaled tobramycin have not 
found a significant increase in the resistance of P. 
aeruginosa compared to placebo or no treatment [33-35]. 
However, in the Barker et al. trial, four of the patients 
receiving TSI had resistant isolates of P. aeruginosa based 
on the current breakpoints for parenteral tobramycin (≥ 16 
µg/ml) [35]. 
 Given the high bronchial concentration reached by 
inhaled antibiotics, much higher breakpoints have been 
proposed for inhaled tobramycin (susceptible ≤ 64µg/ml and 
resistent ≥128µ/ml)[57]. 
SUMMARY 
 To summarise, trials conducted with inhaled tobramycin 
in chronic P. aeruginosa bronchial infection patients with 
non-CF bronchiectasis have shown clinical improvement and 
reduction in bacterial density. Further trials are needed to 
determine the most effective dose and administration 
protocol in these patients. Based on the current evidence, 
recommendations cannot be made regarding the use of 
inhaled tobramycin to treat exacerbations. Although no 
systemic toxicity has been reported with this treatment, 
patients with known kidney disease or ear disorders should 
be treated with caution. Moreover, adverse respiratory 
effects are reported to be more common in non-CF patients 
that in CF patients, who are generally non-smokers and 
younger. Research is ongoing into the possibility of 
combining tobramycin with other antibiotics to increase its 
antibacterial activity. 
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